Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBT-401-1S Phase 1 in healthy volunteers
NCT03482648Phase 1Completed
- Sponsor
- Bridge Biotherapeutics
- Start
- Mar 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BBT-401 in ulcerative colitis (UC) (2 arms), sponsored by Bridge Biotherapeutics. Primary endpoint: Treatment Emergent Adverse Events. Started Mar 2018; status: completed.
02
Drugs
BBT-401
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03482648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03482648.